{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "the-recitals", "type": "clause", "offset": [29, 41]}], "size": 4, "snippet": "has the meaning set forth in the Recitals.", "samples": [{"hash": "l2aUoVLittd", "uri": "/contracts/l2aUoVLittd#rd-activities", "label": "Loan Agreement (Virios Therapeutics, Inc.)", "score": 35.765229295, "published": true}, {"hash": "iBwvFmWZV4z", "uri": "/contracts/iBwvFmWZV4z#rd-activities", "label": "Share Exchange Agreement (Virios Therapeutics, Inc.)", "score": 35.765229295, "published": true}, {"hash": "fzL42UIHdnF", "uri": "/contracts/fzL42UIHdnF#rd-activities", "label": "Loan Agreement (Virios Therapeutics, Inc.)", "score": 35.765229295, "published": true}], "hash": "8147307746bce1e7e7ce0d9d9441a89a", "id": 1}, {"snippet_links": [{"key": "rd-plans", "type": "clause", "offset": [70, 79]}], "size": 4, "snippet": "has the meaning set forth in Section 4.3.3 (Contents of Collaboration R&D Plans)", "samples": [{"hash": "fyyY1aCKvdq", "uri": "/contracts/fyyY1aCKvdq#rd-activities", "label": "Collaboration Agreement (Voyager Therapeutics, Inc.)", "score": 26.8453114305, "published": true}, {"hash": "d4YNOZGiWoQ", "uri": "/contracts/d4YNOZGiWoQ#rd-activities", "label": "Collaboration Agreement (Voyager Therapeutics, Inc.)", "score": 26.839835729, "published": true}, {"hash": "6A88nyJpxXr", "uri": "/contracts/6A88nyJpxXr#rd-activities", "label": "Collaboration Agreement (Voyager Therapeutics, Inc.)", "score": 26.7686516085, "published": true}], "hash": "ba34fd339a9bbaede650bdaecb9748a1", "id": 2}, {"snippet_links": [{"key": "research-and-development-activities", "type": "definition", "offset": [4, 39]}, {"key": "to-information", "type": "clause", "offset": [59, 73]}, {"key": "performance-of-research-and-development", "type": "clause", "offset": [79, 118]}, {"key": "design-phases", "type": "clause", "offset": [166, 179]}, {"key": "regulatory-approvals", "type": "definition", "offset": [195, 215]}, {"key": "regulatory-authorities", "type": "clause", "offset": [240, 262]}, {"key": "completion-of-the", "type": "clause", "offset": [272, 289]}, {"key": "by-a-party", "type": "clause", "offset": [294, 304]}, {"key": "on-behalf-of", "type": "clause", "offset": [308, 320]}, {"key": "such-party", "type": "clause", "offset": [321, 331]}], "size": 3, "snippet": "or \u201cResearch and Development Activities\u201d mean with respect to Information, the performance of research and development activities (conceptual, preliminary, and final design phases) and obtaining Regulatory Approvals for LTR and/or LTA from Regulatory Authorities, through completion of the PIE by a Party or on behalf of such Party. For the sake of clarity, R&D Activities shall be understood to run through the end of lead test assembly demonstration, and R&D Activities shall not be construed to include the supply of batch reloads.", "samples": [{"hash": "g3UxBmR3yXw", "uri": "/contracts/g3UxBmR3yXw#rd-activities", "label": "Co Ownership Agreement", "score": 31.340862423, "published": true}, {"hash": "kYgVczPYGYm", "uri": "/contracts/kYgVczPYGYm#rd-activities", "label": "Ip Annex (LIGHTBRIDGE Corp)", "score": 28.1724845996, "published": true}, {"hash": "boa4rNQCvT2", "uri": "/contracts/boa4rNQCvT2#rd-activities", "label": "Co Ownership Agreement (LIGHTBRIDGE Corp)", "score": 28.1724845996, "published": true}], "hash": "a775ce9d4af4ba107736e73b027f5325", "id": 3}, {"snippet_links": [{"key": "research-and-development-activities", "type": "definition", "offset": [6, 41]}, {"key": "related-to", "type": "clause", "offset": [42, 52]}, {"key": "selection-of-candidate-compounds", "type": "clause", "offset": [57, 89]}, {"key": "work-of-the", "type": "definition", "offset": [105, 116]}, {"key": "screening-activities", "type": "clause", "offset": [136, 156]}, {"key": "feasibility-study", "type": "clause", "offset": [158, 175]}, {"key": "project-activities", "type": "definition", "offset": [192, 210]}, {"key": "preparation-of-the", "type": "clause", "offset": [226, 244]}, {"key": "feasibility-plan", "type": "definition", "offset": [261, 277]}, {"key": "project-proposal", "type": "definition", "offset": [291, 307]}, {"key": "project-plan", "type": "clause", "offset": [325, 337]}, {"key": "relating-to", "type": "definition", "offset": [413, 424]}, {"key": "in-development", "type": "definition", "offset": [459, 473]}, {"key": "rd-collaboration", "type": "definition", "offset": [485, 502]}, {"key": "for-clarity", "type": "clause", "offset": [504, 515]}, {"key": "activities-include", "type": "clause", "offset": [525, 543]}, {"key": "new-technology", "type": "clause", "offset": [548, 562]}, {"key": "the-activities", "type": "clause", "offset": [578, 592]}, {"key": "the-total", "type": "clause", "offset": [612, 621]}, {"key": "scope-activities", "type": "clause", "offset": [691, 707]}], "size": 3, "snippet": "means research and development activities related to the selection of Candidate Compounds (including the work of the Exploratory Team), Screening Activities, Feasibility Study and Development Project activities (including the preparation of the Screening Plan, Feasibility Plan, Development Project Proposal, the Development Project Plan and any revisions thereto), as well as research and development activities relating to any Strain or Compound or Product in development within the R&D Collaboration. For clarity, the R&D Activities include the New Technology Activities and the activities in the exercise of the TOTAL R&D Option. For clarity, R&D Activities do not encompass Improvement Scope Activities.", "samples": [{"hash": "g1EGTu8IJWu", "uri": "/contracts/g1EGTu8IJWu#rd-activities", "label": "Technology License, Development, Research and Collaboration Agreement (Amyris, Inc.)", "score": 21.7173169062, "published": true}, {"hash": "gOrwnIYtIRd", "uri": "/contracts/gOrwnIYtIRd#rd-activities", "label": "Technology License, Development, Research and Collaboration Agreement (Amyris, Inc.)", "score": 21.6625598905, "published": true}, {"hash": "f0jQMbI8zEb", "uri": "/contracts/f0jQMbI8zEb#rd-activities", "label": "Technology License, Development, Research and Collaboration Agreement (Amyris, Inc.)", "score": 21.4873374401, "published": true}], "hash": "f6f1e8cf51256ea60d27faa91f99d374", "id": 4}, {"snippet_links": [{"key": "other-activities", "type": "definition", "offset": [31, 47]}, {"key": "in-order-to", "type": "clause", "offset": [74, 85]}, {"key": "the-information", "type": "clause", "offset": [93, 108]}, {"key": "rd-plan", "type": "clause", "offset": [127, 135]}, {"key": "other-tests", "type": "clause", "offset": [145, 156]}, {"key": "from-time-to-time", "type": "clause", "offset": [207, 224]}, {"key": "rd-committee", "type": "definition", "offset": [232, 245]}, {"key": "with-respect-to", "type": "clause", "offset": [246, 261]}, {"key": "the-subject", "type": "clause", "offset": [262, 273]}, {"key": "female-product", "type": "definition", "offset": [274, 288]}], "size": 3, "snippet": "means those tests, studies and other activities set forth in, or required in order to obtain the information set forth in, the R&D Plan and such other tests, studies and other activities as may be specified from time to time by the R&D Committee with respect to the subject Female Product.", "samples": [{"hash": "k3vplEZFM6J", "uri": "/contracts/k3vplEZFM6J#rd-activities", "label": "Non Exclusive Patent License (Cutera Inc)", "score": 21.0, "published": true}, {"hash": "h0P0Emmryzz", "uri": "/contracts/h0P0Emmryzz#rd-activities", "label": "Non Exclusive Patent License (Cynosure Inc)", "score": 21.0, "published": true}, {"hash": "1Y11yxr7vJF", "uri": "https://ir.cutera.com/static-files/54259f39-52ff-4b9f-8935-cfe077c00aa1", "label": "ir.cutera.com", "score": 10.1704312115, "published": false}], "hash": "b66f81f039aaa4fd30208e460dcec50f", "id": 5}, {"snippet_links": [], "size": 2, "snippet": "means systematic investigation or experimentation activities:", "samples": [{"hash": "avJRwBNDzZv", "uri": "http://citeseerx.ist.psu.edu/viewdoc/download;jsessionid=4997DA2F7AA79EDCA11D66F046469C90?doi=10.1.1.126.6825&rep=rep1&type=pdf", "label": "citeseerx.ist.psu.edu", "score": 5.0, "published": false}, {"hash": "71fmgQutRQY", "uri": "https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=a9577b241220eb964fb3310b094ae9c10a3bb308", "label": "citeseerx.ist.psu.edu", "score": 3.0, "published": false}], "hash": "19a0e1b0f6172ef94e8c4c6e89afd5ac", "id": 6}, {"snippet_links": [{"key": "research-and-development-activities", "type": "definition", "offset": [10, 45]}, {"key": "by-the-parties", "type": "clause", "offset": [56, 70]}, {"key": "this-agreement", "type": "clause", "offset": [77, 91]}, {"key": "statement-of-work", "type": "definition", "offset": [108, 125]}], "size": 2, "snippet": "means any research and development activities conducted by the parties under this Agreement pursuant to the Statement of Work.", "samples": [{"hash": "2TeQVzg5T7q", "uri": "/contracts/2TeQVzg5T7q#rd-activities", "label": "Joint Development Agreement (Decarbonization Plus Acquisition Corp III)", "score": 32.780971937, "published": true}, {"hash": "aixbA6W8OdH", "uri": "/contracts/aixbA6W8OdH#rd-activities", "label": "Joint Development Agreement (Decarbonization Plus Acquisition Corp III)", "score": 32.6057494867, "published": true}], "hash": "bb6096661a9d1e3b237bff4c6cc3bcef", "id": 7}, {"snippet_links": [], "size": 2, "snippet": "has the meaning set forth in Section 2.06(a).", "samples": [{"hash": "9M2NzwMMzw7", "uri": "/contracts/9M2NzwMMzw7#rd-activities", "label": "Asset Purchase Agreement (Spectrum Pharmaceuticals Inc)", "score": 30.0431211499, "published": true}], "hash": "2548de0dd5da1c332fae734ea388ddca", "id": 8}, {"snippet_links": [{"key": "discovery-of", "type": "clause", "offset": [34, 46]}, {"key": "research-tools", "type": "clause", "offset": [71, 85]}, {"key": "services-for", "type": "clause", "offset": [145, 157]}, {"key": "quality-of-life", "type": "definition", "offset": [267, 282]}, {"key": "clinical-trials", "type": "definition", "offset": [337, 352]}], "size": 2, "snippet": "means research, including for the discovery of clinical and commercial research tools, products (including components of products), therapies or services for the treatment, prevention, palliation, delay and/or diagnosis of diseases or disorders or the improvement of quality of life. R&D Activities shall include, but not be limited to, Clinical Trials.", "samples": [{"hash": "jRUXMstJGCw", "uri": "/contracts/jRUXMstJGCw#rd-activities", "label": "Data Structuring and Curation Agreement (Sema4 Holdings Corp.)", "score": 32.5701574264, "published": true}], "hash": "b59b78a08d24d68be59ed95cf3db9037", "id": 9}, {"snippet_links": [{"key": "research-and-development-activities", "type": "definition", "offset": [10, 45]}, {"key": "schedules-1", "type": "clause", "offset": [102, 113]}], "size": 1, "snippet": "means the research and development activities to be provided by ORGANISATION and further described in Schedules 1 and 2.", "samples": [{"hash": "eXLwiSbKdfy", "uri": "/contracts/eXLwiSbKdfy#rd-activities", "label": "Research and Development", "score": 33.8448620895, "published": true}], "hash": "a4156ec681fee7acebcec2bd196ee581", "id": 10}], "next_curs": "CloSVGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjYLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIWcmQtYWN0aXZpdGllcyMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 32, "snippet": "has the meaning set forth in the Recitals.", "title": "R&D Activities", "id": "rd-activities", "examples": ["As between the Parties, subject to the license grants set forth in this Agreement, AMYRIS shall have sole and exclusive ownership of all right, title and interest on a worldwide basis in and to the AMYRIS Tools IP and MEV Pathway IP conceived and reduced to practice in the performance the R&D Activities and/or the performance of activities on behalf of the JV Company related to a Product or the means of making the Product (\u201cAMYRIS Owned Collaboration IP\u201d).", "Notwithstanding any other provision of this Agreement, TOTAL Background IP shall not be deemed to be introduced as TOTAL Included IP in any aspect of R&D Activities, Improvement Scope Activities, or Commercialization activities without an express election by TOTAL and by following the process set forth in Section 6.1(c)(i) below.", "Notwithstanding any other provision of this Agreement, TOTAL Non-Collaboration IP shall not be deemed to be introduced as TOTAL Included IP in any aspect of R&D Activities, Improvement Scope Activities, or commercialization activities without an express election by TOTAL and by following the process set forth in Section 6.1(c)(i) below.", "Notwithstanding any other provision of this Agreement, AMYRIS Non-Collaboration IP shall not be deemed to be introduced as AMYRIS Included IP in any aspect of R&D Activities, Improvement Scope Activities, or commercialization activities without an express election by AMYRIS and by following the process set forth in Section 6.1(c)(i) below, other than AMYRIS Non-Collaboration IP which is automatically deemed to be AMYRIS Included IP as set forth in Section 6.1(c)(ii).", "As between the Parties, subject to the license grants set forth in this Agreement, AMYRIS and TOTAL shall have joint ownership of all right, title and interest on a worldwide basis in and to the New Tools IP and Main IP conceived and reduced to practice in the performance of the R&D Activities and/or the performance of activities on behalf of the JV Company related to a Product or the means of making the Product, other than TOTAL Owned Collaboration IP (\u201cJointly Owned Collaboration IP\u201d).", "Genzyme shall not use or provide to Voyager any Foundation Provided Materials (as defined in the CHDI Agreement) in the course of performance of any R&D Activities under this Agreement without Voyager\u2019s prior written approval or approval of the DAC.", "The time table for the completion of the R&D Activities included in each Collaboration R&D Plan shall be designed to obtain Human POP Study Completion of the applicable Collaboration Product as soon as reasonably possible.", "Furthermore, a Voyager Program Abandonment shall not have occurred if such failure to initiate or conduct Development activities is a result of a regulatory delay, a force majeure event, or a determination by the PSC or an agreement by the Parties to halt R&D Activities or Development activities for such Agreement Program.", "Following the adoption by the parties of such revised R&D Plan, the parties shall cooperate in good faith to implement and carry out the R&D Activities set out in such R&D Plan.", "Each party shall conduct its day-to-day R&D Activities under the direction and supervision of a project leader designated by such party (the \u201cR&D Leader\u201d)."], "related": [["licensed-activities", "licensed activities", "licensed activities"], ["development-activities", "Development Activities", "Development Activities"], ["covered-activities", "Covered Activities", "Covered Activities"], ["funded-activities", "Funded Activities", "Funded Activities"], ["collaboration-activities", "Collaboration Activities", "Collaboration Activities"]], "related_snippets": [], "updated": "2025-07-06T21:56:50+00:00"}, "json": true, "cursor": ""}}